Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial

Por Beeh KM, Singh D, Di Scala L, Drollmann A
Publicado em 2012-07-01

An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable he...

Por Temam, S, Spicer, J, Farzaneh, F, Soria, J C, Oppenheim, D, McGurk, M, Hollebecque, A, Sarini, J, Hussain, K, Soehrman Brossard, S, Manenti, L, Evers, S, Delmar, P, Di Scala, L, Mancao, C, Feuerhake, F, Andries, L, Ott, M G, Passioukov, A, Delord, J P
Publicado no Ann Oncol (2017)